the percentages are just for price risking - how much do discount the value that product brings to the share price. They have done this accurately in their guidance.
I agree with BP on most of this stuff (except possibly the price target). I think success at the type A meeting is likely to be inhibited by the FDA's clear need for an MSC RCT, we should see scenario 2 or 3 from their report.
Covid breaks the ice for approval on the other products because it is a full RCT and the FDA wants therapies to be approved so they have tools to fight the pandemic. Q4 and Q1 2021 there's going to be a few new therapies for covid approved, I think. Ours will be just one, but it's big for MSB and future products!
if the price tanks after the type A meeting I'll buy a trading parcel.
Updated Broker Report: Bel Potter, page-15
-
- There are more pages in this discussion • 151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |